Literature DB >> 1430096

Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions.

T Brue1, E Caruso, I Morange, T Hoffmann, M Evrin, G Gunz, M Benkirane, P Jaquet.   

Abstract

The monoclonal antibodies (MAbs) obtained in mice immunized with human PRL coupled to an anti-PRL MAb were screened for their ability to distinguish the glycosylated (G-) and nonglycosylated (NG-) forms of PRL. The 431-29 MAb exhibited high affinity binding for NG-PRL but little or no cross-reactivity to G-PRL. Using this antibody in conjunction with other MAbs which equally recognized both forms, we developed 2 immunoradiometric assays which were used to determine the amount of G- and NG-PRL in plasma. In 85 normal subjects, NG-PRL baseline levels averaged 6.6 +/- 3 micrograms/L, and represented 76 +/- 8% of the total PRL immunoreactivity. In 74 pregnant women, this proportion was significantly higher during the last 2 trimesters (84 +/- 4% and 85 +/- 6%), as compared to the first trimester (76 +/- 7%). In 6 healthy volunteers studied over 24 h, 79% of the NG-PRL peaks detected using the cluster algorithm occurred concomitantly to a G-PRL peak. The mean NG-PRL/PRL ratio was significantly higher during NG-PRL pulses (81 +/- 9%) than during valleys (71 +/- 12%). Similarly, this ratio was significantly increased during TRH or metoclopramide stimulated PRL secretion (to 88 +/- 7% and 86 +/- 6%, respectively). We conclude that 1) NG-PRL is the predominant immunoassayable form of PRL in plasma; 2) both G- and NG-PRL are cosecreted but NG-PRL is the main PRL form released during spontaneous or pharmacologically induced PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430096     DOI: 10.1210/jcem.75.5.1430096

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.

Authors:  R Guido; S Valenti; L Foppiani; D De Martini; M Cossu; M Giusti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Secretion of 23 kDa and glycosylated prolactin by rat pituitary cell culture in serum-free media: a comparative morphological, cyto- and immunochemical study.

Authors:  F Bollengier; M Espeel; A Matton; A Mahler; L Vanhaelst
Journal:  Endocrine       Date:  1995-01       Impact factor: 3.633

3.  Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.

Authors:  G M Gambino; P Beck-Peccoz; S Borgato; G Faglia; A Spada; L Persani
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

4.  Circulating levels of growth hormone, insulin-like growth factor-I and prolactin in normal, growth retarded and anencephalic human fetuses.

Authors:  M Arosio; D Cortelazzi; L Persani; E Palmieri; G Casati; A M Baggiani; G Gambino; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

5.  The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin.

Authors:  M Shelikoff; A J Sinskey; G Stephanopoulos
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

6.  Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance.

Authors:  T Hoffmann; C Penel; C Ronin
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.